Literature DB >> 6284696

The comparative activities of N-formimidoyl theinamycin (MK0787), moxalactam, cefotaxime and cefoperazone against Yersinia enterocolitica and Listeria monocytogenes.

V I Ahonkhai, M F Sierra, C E Cherubin, M A Shulman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6284696     DOI： 10.1093/jac/9.5.411

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  7 in total

1.  Bacterial meningitis in the 1980s, or one drug or many?

Authors:  C E Cherubin; R H Eng
Journal:  West J Med       Date:  1987-09

Review 2.  Antibiotic susceptibilities of Listeria: in vitro studies.

Authors:  E P Espaze; A E Reynaud
Journal:  Infection       Date:  1988       Impact factor: 3.553

Review 3.  In vitro activity of imipenem--a review.

Authors:  I Braveny
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

Review 4.  Antimicrobial chemotherapy of human infection due to Listeria monocytogenes.

Authors:  E M Jones; A P MacGowan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-03       Impact factor: 3.267

Review 5.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

Review 6.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

Review 7.  Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-03       Impact factor: 9.546
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.